Xbrane Biopharma AB 2022 IR
The report highlights Xbrane's transition into a commercial-phase biopharmaceutical company, marked by the European Commission's marketing authorization of its first biosimilar, Ximluci_x0000_, for treating serious eye diseases. The company expanded its pipeline with preclinical candidates in oncology and secured a licensing agreement with Biogen for BIIB801. On sustainability, Xbrane focused on health equality, became Great Place to Work certified for the second consecutive year, and established a baseline for its greenhouse gas emissions under the GHG Protocol.
Company: Xbrane Biopharma AB
Sector: Health Care
Country: Sweden
Year: 2022
Type: IR
Pages: 92
Xbrane Biopharma AB
Annual And Sustainability Report
The report highlights Xbrane's transition into a commercial-phase biopharmaceutical company, marked by the European Commission's marketing authorization of its first biosimilar, Ximluci_x0000_, for treating serious eye diseases. The company expanded its pipeline with preclinical candidates in oncology and secured a licensing agreement with Biogen for BIIB801. On sustainability, Xbrane focused on health equality, became Great Place to Work certified for the second consecutive year, and established a baseline for its greenhouse gas emissions under the GHG Protocol.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women on Board
Women in Management
Employees